<DOC>
	<DOC>NCT00387881</DOC>
	<brief_summary>This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.</brief_summary>
	<brief_title>TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>At least a 6 month history of probably migraine (6 migraine attacks per month) Males and women of childbearing potential on a adequate contraception. Physician diagnosis of migraine; history of triptan or ergot use; history of headache prophylaxis use Pregnant and/or nursing mother History of cardiovascular disease. Uncontrolled hypertension. Basilar or Hemiplegic migraine History of stroke or transient ischemic attacks (TIA). History of epilepsy or treated with antiepileptics within the past 5 years. Impaired hepatic or renal function. History of gastrointestinal bleeding or ulceration. Allergy or hypersensitivity to Aspirin or any other NSAID. Allergy or hypersensitivity to triptans. Participated in an investigational drug trial in the previous 4 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sumatriptan succinate,</keyword>
	<keyword>naproxen sodium,</keyword>
	<keyword>parallel group,</keyword>
	<keyword>double-blind,</keyword>
	<keyword>placebo-controlled,</keyword>
	<keyword>Combination product,</keyword>
	<keyword>migrainous headache</keyword>
	<keyword>Probable migraine, a sub-type of Migraine</keyword>
	<keyword>probable migraine,</keyword>
</DOC>